KALARIS THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $225.3M | $201.7M |
| FY2022 | — | $224.5M | $106.1M |
| FY2023 | — | $-45.0M | $90.1M |
| FY2024 | — | $-96.6M | $1.6M |
| FY2025 | — | $78.8M | $98.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $225.3M | $201.7M |
| FY2022 | — | $224.5M | $106.1M |
| FY2023 | — | $-45.0M | $90.1M |
| FY2024 | — | $-96.6M | $1.6M |
| FY2025 | — | $78.8M | $98.1M |